The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

Advisers to the Food and Drug Administration met Thursday to help decide which variant of the virus that causes COVID should ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

An FDA advisory committee unanimously recommended Thursday that the next COVID vaccine should be a monovalent one in the JN.1 ...

19日の米株式市場で米バイオテクノロジー企業ノババックスの株価が急伸した。米規制当局が同社の新型コロナウイルスワクチンを完全に承認したことで、承認遅延や有効性を疑問視するケネディ厚生長官の発言により高まっていた市場の不安が和らいだ。

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...